Prothena Corporation plc has announced a scientific poster presentation for its TDP-43 CYTOPE® program at Neuroscience 2025, hosted by the Society for Neuroscience (SfN) in San Diego, California. The presentation, scheduled for November 19, 2025, will detail preclinical data on a cell-internalizing CYTOPE® targeting pTDP-43 in a mouse model of amyotrophic lateral sclerosis (ALS). According to Prothena, systemically-administered TDP-43 CYTOPE® demonstrated rapid brain distribution, efficient cytosolic internalization, and significant reduction of intracellular pTDP-43 pathology in preclinical models. The results from these studies will be presented at the upcoming conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119275479) on November 19, 2025, and is solely responsible for the information contained therein.